



**EUROPEAN COMMISSION**  
HEALTH & CONSUMERS DIRECTORATE-GENERAL  
Public Health and Risk Assessment  
**Risk assessment**

## **Scientific Committee on Consumer Safety**

**5<sup>th</sup> meeting of the WG 'Cosmetic Ingredients' – 7 October 2009**

### **Minutes**

#### **1. WELCOME AND APOLOGIES**

The Chair of the working group (WG) welcomed the participants and communicated the apologies received.

#### **2. ADOPTION OF THE AGENDA**

The draft agenda was adopted (annex 1).

#### **3. DECLARATION OF INTEREST ON MATTERS OF THE AGENDA**

No member declared any interest that could prevent him/her from participating in the discussion of the items on the agenda.

#### **4. DRAFT OPINIONS**

Draft opinions on the following substances were discussed by the Working Group:

- 4.1. Chloro methyl isothiazolinone / methyl isothiazolinone (CMI/MI)
- 4.2. Cyclomethicone (D4)
- 4.3. Clarification on Choline salts and esters
- 4.4. Citric Acid (and) Silver Citrate
- 4.5. CMR substances, borate
- 4.6. S74, Polysilicone-15
- 4.7. Vitamin K1
- 4.8. Erythrosine
- 4.9. Melatonin

The draft opinions on Clarification on Choline salts and esters and on Citric Acid (and) Silver Citrate were addressed to the plenary meeting of 13 October 2009 for formal adoption.

**5. PROGRESS REPORTS**

The members of the WG were updated on the progress of the following mandates, for which no draft opinion has been received yet:

- 5.1. P81, Zinc pyrithione

**6. OBJECTION TO PREVIOUS OPINIONS**

The WG discussed comments received on the following opinions:

- 6.1. Alkyl (C16, C18, C22) triethylammoniumchloride
- 6.2. Benzophenone-3
- 6.3. Camphor benzalkonium methosulfate

**7. NEW REQUESTS**

- 7.1. P95, Ethyl lauroyl arginate HCl

An objection to the exclusion of use of P95 in oral products has been submitted.

**8. ANY OTHER BUSINESS**

No specific items were raised.

The next meeting will take place on 23 November 2009.

Annex 1: draft agenda

## Annex 1

**Scientific Committee on Consumer Safety (SCCS)  
WG on Cosmetic Ingredients****7 October 2009****DRAFT AGENDA**

1. Welcome and apologies
2. Adoption of the agenda
3. Declaration of interest on matters on the agenda
4. Draft opinions on:
  - 4.1. Chloro methyl isothiazolinone / methyl isothiazolinone (CMI/MI)
  - 4.2. Cyclomethicone (D4)
  - 4.3. Clarification on Choline salts and esters
  - 4.4. Citric Acid (and) Silver Citrate
  - 4.5. CMR substances, borate
  - 4.6. S74, Polysilicone-15
  - 4.7. Vitamin K1
  - 4.8. Erythrosine
  - 4.9. Melatonin
5. Progress reports
  - 5.1. P81, Zinc pyrithione
6. Responses to previous opinions
  - 6.1. Objection to Alkyl (C16, C18, C22) triethylammoniumchloride
  - 6.2. Response to the public consultation on benzophenone-3
  - 6.3. Response to the public consultation on Camphor benzalkonium methosulfate
7. New requests (discussion on rapporteur and/or next steps)
  - 7.1. P95, Ethyl lauroyl arginate HCl
8. Any Other Business